|
已读[73]
发布： 2013/10/23 17:01:24
肝素钠原料药受产能瓶颈影响,全年稳定增长:前三季度普通肝素原料药实现收入21,805.69万元,较上年同期增长15.27%,销量为8,981.25亿单位,较上年同期增长16.67%...
|
|
|
|
|
已读[51]
发布： 2013/10/23 17:01:13
PR Newswire (press release) That connection needs to be made at the national level, and that's why HCA strongly advocates the universal use of prophylactic compression devices or heparin for all women undergoing cesarean delivery." Research suggests that patients delivering by ... and more »
|
|
|
|
|
已读[47]
发布： 2013/10/23 17:01:08
Medscape EuroMax , a randomized trial testing ambulance initiation of bivalirudin vs heparin with or without glycoprotein IIb/IIIa inhibitors in patients with STEMI being transported for primary PCI. LEVANT 2 , the first report of a US-based study required for ... and more »
|
|
|
|
|
已读[117]
发布： 2013/10/23 15:27:28
信立泰(002294)阿立沙坦原料药获批,制剂获批在望,氯吡格雷虽然后有追兵,但有望抓住新版基本药物招标的良机,快速扩张,目前12亿元的份额在60亿元以上的细分市场中还有...
|
|
|
|
|
已读[63]
发布： 2013/10/22 17:00:54
低分子肝素钙制剂增速单季放缓:上半年低分子肝素钙注射液销量为918.68万支,增长40%,实现收入2.92亿元,增长49.72%,三季度由于是传统淡季且前期经销商提前备货,...
|
|
|
|
|
已读[77]
发布： 2013/10/22 17:00:16
(4)常山药业:肝素钠原料药取得CEP证书本周投资策略对于基金等机构投资者来说,由于有最低仓位限制,追求相对收益,因此建议将仓位向医药等防御性板块倾斜,超配医药股;...
|
|
|
|
|
已读[68]
发布： 2013/10/22 16:59:07
(对应销量为8,981.25 亿单位,同比增长16.67%,由于肝素原料药单价同比有所下跌且价格较低的外销订单占比加大,当期销量增速略快于收入增速),目前公司肝素钠原料药...
|
|
|
|
|
已读[57]
发布： 2013/10/22 16:58:56
原料药销售情况稳定,高端产品逐步上量:前三季度公司实现普通肝素原料药销售收入2.18亿元,同比增长15.27%,目前公司肝素钠原料药已通过美国FDA的认证,同时在上半年...
|
|
|
|
|
已读[50]
发布： 2013/10/22 16:58:51
肝素钠原料药受产能瓶颈影响,全年稳定增长:前三季度普通肝素原料药实现收入21,805.69万元,较上年同期增长15.27%,销量为8,981.25亿单位,较上年同期增长16.67%...
|
|
|
|
|
已读[41]
发布： 2013/10/22 16:58:40
MIT Technology Review Blood clotting is produced by a long cascade of protein interactions, culminating in the formation of fibrin, a fibrous protein that seals wounds. Heparin and other blood thinners interfere with this process by targeting several of the reactions that ...
|
|
|
« 上一页 |
查看结果1991-2000共2625
|
下一页 »
|
|
